Skip to main content

HOPA Abstracts

Efficacy of Tixagevimab-Cilgavimab in Preventing SARS-CoV-2 in Patients with Hematologic Malignancies
Abstract #LB02
Read More
Potentially Inappropriate Medication Use and Cognition in Older Women with Breast Cancer
Abstract #LB03
Read More
Safety and Tolerability of an Alternative Capecitabine Dosing Schedule in Patients with Colorectal Cancer
Abstract #LB04
Read More
Biosimilar Uptake and Cost-Savings Analysis Before and After the Implementation of a Pharmacist-Driven Substitution Program Within a National Community Oncology Network
Abstract #CR02
Read More
Bruton Tyrosine Kinase Inhibitors: Real-World Clinical Outcomes in a Diverse Patient Population at a Large Safety Net Hospital
Abstract #CR03
Read More
Clinical Outcomes in Patients with Tumor PD-L1 Less Than 1% Who Received First-Line Nivolumab plus Ipilimumab and 2 Cycles of Chemotherapy versus Chemotherapy Alone for Metastatic NSCLC: Results from CheckMate 9LA
Abstract #CR04
Read More
HOP(A) Springs Eternal
By Bryna Delman Ewachiw, PharmD, BCOP; Mark L. Zangardi, PharmD, BCOP
Read More
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
Abstract #CR01
Read More
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
Abstract #CR02
Read More
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
Abstract #CR03
Read More
Page 11 of 15
Results 101 - 110 of 146